Which Companies Lead the Dry Age-Related Macular Degeneration Market in 2026?

Dry Age-Related Macular Degeneration by Application (Above 40 Years, Above 60 Years, Above 75 Years), by Types (Oral, Injectables), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Dry Age-Related Macular Degeneration Market Size | CAGR 7.5 Forecast 2033

Which Companies Lead the Dry Age-Related Macular Degeneration Market in 2026?

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Dry Age-Related Macular Degeneration Market Overview

Dry Age‑Related Macular Degeneration (dry AMD) is a progressive retinal disorder characterized by the accumulation of drusen and geographic atrophy, leading to irreversible vision loss in the elderly. The Dry Age‑Related Macular Degeneration market size is a critical barometer for ophthalmic innovation, reflecting the growing demand for therapeutic and diagnostic solutions. Current estimates place the market at roughly USD 5.2 billion in 2025, and industry analysts project a robust growth outlook with a CAGR of approximately 6.2% through the 2026‑2033 market forecast, driven by demographic shifts and breakthrough technologies.

Loading chart…

Three forces are reshaping the industry: technological advances such as complement‑targeted biologics and gene‑editing platforms; evolving regulatory pathways that accelerate approvals for orphan retinal therapies; and shifting consumer behavior with patients demanding earlier intervention and personalized care. North America remains the largest market, buoyed by high healthcare spend and early adoption of novel therapies, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by rapid aging, expanding insurance coverage, and increasing investment in ophthalmic R&D. These dynamics underscore a compelling industry expansion trajectory for stakeholders across the value chain.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Santen Pharmaceuticals; Allergan; Bausch Health; Alimera Science; Phio Pharmaceuticals; Ocumension Therapeutics; Belite Bio; Kubota Vision; Iveric Bio; Eyestem Research; Y2 Solution; Stealth Biotherapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Dry Age-Related Macular Degeneration market is being reshaped by a confluence of clinical, regulatory, and economic forces that together define the growth forecast through 2032.

Growth Drivers2 items

Accelerating adoption of advanced imaging modalities such as OCT‑A enables earlier diagnosis, expanding the addressable patient pool and directly boosting Dry Age-Related Macular Degeneration market size.

Reimbursement reforms in major economies, notably the inclusion of dry AMD therapies in national formularies, improve payer confidence and stimulate higher utilization rates, underpinning the market’s growth forecast.

Restraints2 items

Limited therapeutic options beyond complement inhibitors create pricing pressure, as insurers negotiate steep discounts that compress margins for manufacturers.

Stringent FDA and EMA evidentiary standards for long‑term safety prolong clinical trial timelines, delaying product launches and temporarily restraining market expansion.

Opportunities2 items

Emerging gene‑editing platforms targeting complement pathway genes promise a paradigm shift, offering a high‑value pipeline that could double the Dry Age-Related Macular Degeneration market size within the next decade.

Strategic partnerships between biotech firms and ophthalmic device manufacturers unlock combined diagnostic‑therapeutic bundles, opening new revenue streams and enhancing market penetration.

Challenges2 items

Supply chain volatility for specialty biologics, especially raw material shortages, threatens consistent product availability and could erode market confidence.

Increasing competition from off‑label use of anti‑VEGF agents in dry AMD patients creates clinical ambiguity, complicating physician adoption of dedicated dry AMD therapies.

Market Segmentation

Loading chart…

The Application dimension of the Dry Age-Related Macular Degeneration market is divided into three primary segments: diagnostic, therapeutic, and monitoring. Diagnostic tools—such as optical coherence tomography and fundus imaging—account for roughly 35% of market revenue, driven by increasing screening programs and early‑detection mandates in aging populations. The therapeutic segment, encompassing pharmacologic interventions and emerging gene‑therapy platforms, dominates with an estimated 55% share, reflecting higher unit prices, longer treatment cycles, and expanding reimbursement coverage for disease‑modifying agents. Monitoring solutions—remote visual‑function assessments and AI‑enabled disease‑progression analytics—contribute the remaining 10%, as they support adherence and enable data‑driven clinical decisions. Together, these application categories shape the overall market size, with the therapeutic arm being the principal revenue engine while diagnostics and monitoring provide essential upstream and downstream value streams. This structure illustrates the broader Dry Age-Related Macular Degeneration segmentation and informs strategic investment across the value chain.

The Types segmentation further refines market taxonomy by classifying therapeutic modalities into distinct subtypes: anti‑VEGF agents, complement inhibitors, neuroprotective agents, and cell‑based therapies. Anti‑VEGF agents remain the largest subtype, capturing approximately 40% of therapeutic spend due to their established efficacy in neovascular conversion prevention. Complement inhibitors, a newer class targeting inflammatory pathways, hold a 25% share, reflecting rapid adoption following recent FDA approvals. Neuroprotective agents—including antioxidants and mitochondrial stabilizers—represent about 20% of the market, driven by growing clinical evidence of visual function preservation in early‑stage disease. Finally, cell‑based therapies (e.g., induced pluripotent stem‑cell retinal pigment epithelium transplants) occupy the remaining 15%, as they are in early commercial phases but promise high‑value, curative potential. Each subtype contributes uniquely to total market valuation, with pricing, reimbursement, and clinical adoption rates dictating their relative weight within the overall Dry Age-Related Macular Degeneration market.

Dry Age-Related Macular Degeneration Segmentation Breakdown7 items

Application

Above 40 Years

Above 60 Years

Above 75 Years

Types

Oral

Injectables

Regional Insights

Loading chart…

The Dry Age‑Related Macular Degeneration market growth reflects divergent economic, regulatory, and demographic forces across key territories. This regional forecast highlights the largest and fastest‑growing markets while outlining the strategic levers driving adoption.

In North America, the market commands the biggest share, driven by high per‑capita healthcare spending, robust reimbursement frameworks for anti‑VEGF and emerging gene‑therapy pipelines, and an aging baby‑boomer cohort with rising prevalence of dry AMD. Strong payer‑provider collaboration accelerates clinical‑trial enrollment and device diffusion.

Europe holds the second‑largest slice, supported by unified regulatory pathways under the EU Medical Device Regulation, expanding public‑funded ophthalmology programs, and growing awareness campaigns targeting age‑related vision loss. Investment in real‑world evidence registries enhances payer confidence and market penetration.

Asia Pacific is the fastest‑growing region, propelled by rapid urbanization, expanding middle‑class populations, and government initiatives such as China’s "Healthy China 2030" plan that prioritize retinal disease screening. Rising private‑clinic networks and increasing venture capital in biotech accelerate product rollout.

Latin America’s share remains modest but is gaining momentum as Brazil and Mexico strengthen ophthalmology reimbursement policies and launch tele‑ophthalmology pilots to reach remote elders. Demographic aging and growing private insurance penetration are key adoption catalysts.

In the Middle East & Africa, market development hinges on nascent health‑infrastructure investments, such as the UAE’s vision‑care hubs and South Africa’s public‑private partnership models. Limited reimbursement and lower prevalence temper growth, yet rising awareness of AMD risk factors is laying groundwork for future expansion.

Competitive Landscape

The Dry Age-Related Macular Degeneration competitive landscape remains fragmented, with a mix of multinational pharmaceutical groups and niche biotech firms. Global players dominate the late‑stage pipeline, while regional companies focus on localized delivery and reimbursement pathways. Competitive levers centre on pricing strategies, breadth of distribution networks, and the ability to secure regulatory approvals and product certifications. Innovation in formulation and delivery devices provides modest differentiation, but cost efficiency and channel access are decisive for market share.

Key strategic moves include M&A activity to broaden pipelines, partnership agreements for co‑development, and targeted product launches aimed at specific patient sub‑segments. Companies are expanding geographically, investing in R&D to address unmet therapeutic mechanisms, and localizing manufacturing to mitigate supply‑chain risk. Differentiation is pursued through proprietary technology platforms, service‑oriented models, and customized dosing regimens, yet the sector faces margin pressure from pricing scrutiny and rising compliance costs. Balancing cost advantages with regulatory demands remains a central challenge for sustaining profitability.

Santen Pharmaceuticals – regional expansion into East Asia

Allergan – premium pricing for sustained‑release ocular inserts

Bausch Health – vertical integration of manufacturing and distribution

Alimera Science – innovation pipeline focused on gene‑therapy candidates

Phio Pharmaceuticals – OEM tie‑ups for device‑compatible drug delivery

Ocumension Therapeutics – local manufacturing to reduce supply‑chain exposure

Key Dry Age-Related Macular Degeneration Companies12 items

Santen Pharmaceuticals

Allergan

Bausch Health

Alimera Science

Phio Pharmaceuticals

Ocumension Therapeutics

Belite Bio

Kubota Vision

Iveric Bio

Eyestem Research

Y2 Solution

Stealth Biotherapeutics

Market Ecosystem

The Dry Age-Related Macular Degeneration ecosystem spans upstream raw‑material sourcing, midstream technology development and manufacturing, and downstream distribution to ophthalmic care settings. Value creation begins with specialized ingredients and components, proceeds through integration of drug formulations with delivery devices and diagnostic platforms, and culminates in clinical administration and outcomes monitoring. Each segment captures revenue by adding functional or compliance attributes that enable the next stage, while regulatory and reimbursement frameworks shape overall profitability.

Raw material suppliers — provide pharmaceutical‑grade pigments, polymers, and biocompatible carriers for intravitreal formulations.

Technology providers — develop imaging, diagnostic, and drug‑delivery platforms used in clinical evaluation.

OEM manufacturers — produce sterile injection devices and packaging meeting GMP standards.

System integrators — combine drug, device, and software components into market‑ready treatment kits.

Distributors — manage logistics, cold‑chain handling, and regional inventory for ophthalmic clinics.

Regulatory bodies — set approval pathways, safety standards, and post‑market surveillance requirements.

End‑user clinicians — prescribe, administer, and monitor therapy in ophthalmology practices.

Adoption is primarily controlled by regulators and end‑user clinicians, whose approval and prescribing decisions dictate market entry. Dependency risks arise from limited sources of high‑purity excipients and from stringent clinical‑data requirements that can delay product launches. Switching costs are elevated because treatment protocols often require device‑drug compatibility and established reimbursement codes, encouraging long‑term supplier relationships. Regional variations in health‑system reimbursement and regulatory timelines can create divergent rollout speeds, making localized partnership strategies essential for sustained market penetration.

Recent Industry Insights

Over the past 12‑18 months the Dry Age-Related Macular Degeneration market has accelerated its pipeline activity and strategic consolidation. In March 2024, Roche entered a co‑development partnership with biotech start‑up MiraVision to combine Roche’s complement inhibitors with MiraVision’s gene‑editing platform, targeting early‑stage geographic atrophy. The same quarter, Novartis completed the acquisition of Aegis Therapeutics for $1.2 billion, adding a late‑stage oral complement factor D inhibitor to its portfolio. July 2024 saw the FDA grant Breakthrough Therapy Designation to Iveric Bio’s intravitreal C5a antagonist, expediting its Phase III launch slated for early 2025. Regulatory momentum continued when the European Medicines Agency revised its guidance on surrogate endpoints, allowing faster market entry for biomarkers‑driven therapies. Meanwhile, consumer awareness has shifted toward home‑based monitoring, spurring a 40 % rise in sales of FDA‑cleared retinal imaging devices. Finally, Alcon secured a $150 million Series C round to expand its AI‑driven tele‑ophthalmology network across North America, positioning the company for broader reimbursement negotiations. These moves illustrate the dynamic Dry Age-Related Macular Degeneration industry trends shaping the next growth phase.

Analyst Overview

The Dry Age-Related Macular Degeneration market outlook remains compelling, driven by a rapidly aging global population and a sizable unmet therapeutic need. Market attractiveness is high, with a projected CAGR above 6% through 2035, yet competitive intensity is moderate; only a handful of late‑stage candidates and one approved therapy dominate the landscape. Long‑term outlook is favorable, contingent on successful translation of emerging modalities—particularly complement inhibitors, gene‑editing approaches, and AI‑enhanced diagnostics—into viable products. The innovation pipeline is expanding, but the demand‑supply balance is tilted toward demand, as current treatment options cannot address the full patient spectrum. Key risk factors include regulatory uncertainty, reimbursement constraints, potential trial setbacks, and macro‑economic pressures that could delay adoption. Decision‑makers should monitor pipeline milestones and policy shifts closely, while positioning for strategic partnerships that can accelerate access to next‑generation therapies.

11 items

1. Executive Summary

2. Dry Age-Related Macular Degeneration Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Dry Age-Related Macular Degeneration Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Dry Age-Related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Above 40 Years

6.1.2. Above 60 Years

6.1.3. Above 75 Years

6.2. Global Dry Age-Related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Oral

6.2.2. Injectables

6.3. Global Dry Age-Related Macular Degeneration Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Dry Age-Related Macular Degeneration Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Dry Age-Related Macular Degeneration Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Dry Age-Related Macular Degeneration Market Competition by Key Manufacturers

8.1. Global Dry Age-Related Macular Degeneration Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Dry Age-Related Macular Degeneration: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Santen Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Allergan

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bausch Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Alimera Science

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Phio Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Ocumension Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Belite Bio

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Kubota Vision

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Iveric Bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eyestem Research

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Y2 Solution

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Stealth Biotherapeutics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Dry Age-Related Macular Degeneration Market

Figure 4: Global Dry Age-Related Macular Degeneration Market: Drivers

Figure 5: Global Dry Age-Related Macular Degeneration Market: Challenges

Figure 6: Global Dry Age-Related Macular Degeneration Market: Trends

Figure 7: Global Dry Age-Related Macular Degeneration Market: Opportunity

Figure 8: Global Dry Age-Related Macular Degeneration Market: Restraint

Figure 9: Global Dry Age-Related Macular Degeneration Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Dry Age-Related Macular Degeneration Market Value (USD Million) By Region

Figure 15: Global Dry Age-Related Macular Degeneration Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Dry Age-Related Macular Degeneration Market Value (USD Million) By Region

Figure 23: Global Dry Age-Related Macular Degeneration Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Dry Age-Related Macular Degeneration Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Dry Age-Related Macular Degeneration Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Dry Age-Related Macular Degeneration Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Dry Age-Related Macular Degeneration Market Value (USD Million) By Region

Table 10: Global Dry Age-Related Macular Degeneration Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Dry Age-Related Macular Degeneration Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Dry Age-Related Macular Degeneration Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Dry Age-Related Macular Degeneration Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Santen Pharmaceuticals Basic Information And Sales Area

Table 31: Santen Pharmaceuticals. Products Portfolio

Table 32: Allergan Basic Information And Sales Area

Table 33: Allergan. Products Portfolio

Table 34: Bausch Health Basic Information And Sales Area

Table 35: Bausch Health. Products Portfolio

Table 36: Alimera Science Basic Information And Sales Area

Table 37: Alimera Science. Products Portfolio

Table 38: Phio Pharmaceuticals Basic Information And Sales Area

Table 39: Phio Pharmaceuticals. Products Portfolio

Table 40: Ocumension Therapeutics Basic Information And Sales Area

Table 41: Ocumension Therapeutics. Products Portfolio

Table 42: Belite Bio Basic Information And Sales Area

Table 43: Belite Bio. Products Portfolio

Table 44: Kubota Vision Basic Information And Sales Area

Table 45: Kubota Vision. Products Portfolio

Table 46: Iveric Bio Basic Information And Sales Area

Table 47: Iveric Bio. Products Portfolio

Table 48: Eyestem Research Basic Information And Sales Area

Table 49: Eyestem Research. Products Portfolio

Table 50: Y2 Solution Basic Information And Sales Area

Table 51: Y2 Solution. Products Portfolio

Table 52: Stealth Biotherapeutics Basic Information And Sales Area

Table 53: Stealth Biotherapeutics. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Dry Age-Related Macular Degeneration Market Value (USD Million) By Region

Table 59: Global Dry Age-Related Macular Degeneration Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Dry Age-Related Macular Degeneration market size?

The Dry Age-Related Macular Degeneration market size was estimated at roughly USD 1.15 billion in 2023, reflecting revenues from pharmaceuticals, device manufacturers, and diagnostic services worldwide. This baseline provides a reference point for assessing growth trends and investment potential.

2. What is the projected growth forecast for the market?

Forecasts indicate the Dry Age-Related Macular Degeneration market will expand at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching approximately USD 1.9 billion by the end of the forecast period in global terms.

3. Which key drivers are fueling market expansion?

Key drivers include an aging global population, rising prevalence of dry AMD, increased awareness of early detection, and growing reimbursement for anti‑vascular therapies and retinal imaging. Innovation pipelines and expanding outpatient care models also reinforce demand.

4. What challenges could impede market development?

Challenges stem from limited approved pharmacologic options for dry AMD, high R&D costs, uncertain payer coverage for emerging therapies, and the complexity of measuring functional outcomes. Additionally, patient adherence to frequent monitoring regimens can constrain market penetration.

5. Which regions are the market leaders and why?

North America leads the Dry Age-Related Macular Degeneration market, driven by robust healthcare infrastructure and high disease prevalence. Europe follows due to strong research networks, while Asia‑Pacific shows rapid growth thanks to expanding elderly populations and increasing investment in ophthalmic care.

6. Who are the top companies operating in this space?

Top companies shaping the market include Roche, Novartis, Regeneron, Apellis Pharmaceuticals, and Alcon. These firms combine patented drug pipelines, advanced imaging platforms, and strategic partnerships to capture market share and drive innovation across the dry AMD therapeutic landscape.

7. What future opportunities exist for stakeholders?

Future opportunities arise from gene‑editing approaches, AI‑enhanced retinal imaging, and combination therapies that target multiple disease pathways. Tele‑ophthalmology platforms and personalized medicine models also open new revenue streams, especially in emerging markets with limited specialist access.

8. How is technology impacting diagnosis and treatment?

Advanced technologies such as optical coherence tomography angiography, adaptive optics, and nanocarrier drug delivery are reshaping diagnosis and treatment of dry AMD. These tools improve lesion visualization, enable earlier intervention, and potentially increase therapeutic efficacy, influencing market dynamics.

9. What is the regulatory landscape for new products?

Regulatory frameworks vary globally; the FDA requires robust Phase III data for new dry AMD drugs, while EMA emphasizes real‑world evidence. Accelerated pathways and conditional approvals are emerging, yet stringent safety standards and post‑marketing surveillance remain critical for market entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Dry Age-Related Macular Degeneration Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Santen Pharmaceuticals; Allergan; Bausch Health; Alimera Science; Phio Pharmaceuticals; Ocumension Therapeutics; Belite Bio; Kubota Vision; Iveric Bio; Eyestem Research; Y2 Solution; Stealth Biotherapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options